Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087096 · ClinicalTrials.gov registry record · Phase 4
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT04087096: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT04087096 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04087096, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
Interventions
- DRUG Placebo
- DRUG Denosumab
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04087096
The ClinicalTrials.gov registry entry for NCT04087096 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04087096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04087096 about?
NCT04087096 is a clinical study titled "Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery". Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
What is the current status of trial NCT04087096?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2020-08-24. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT04087096?
The interventions under investigation include: Placebo (DRUG), Denosumab (DRUG), Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT04087096?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.